| Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV (NCT02032901) | Bristol-Myers Squibb | 2014-01-01 |
| Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment (NCT03090035) | Sheikh Zayed Medical College | 2014-01-01 |
| Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C (NCT01899092) | Tacere Therapeutics, Inc. | 2014-01-01 |
| A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113) (NCT01770223) | Merck Sharp & Dohme LLC | 2014-01-01 |
| UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis (NCT01973049) | Bristol-Myers Squibb | 2013-12-01 |
| The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients (NCT02063607) | Nanogen Pharmaceutical Biotechnology Joint Stock Company | 2013-12-01 |
| HCV Treatment in HIV Co-Infected Patients in Asia (NCT01838772) | amfAR, The Foundation for AIDS Research | 2013-12-01 |
| UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects (NCT01979939) | Bristol-Myers Squibb | 2013-12-01 |
| Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection (NCT02294136) | Icahn School of Medicine at Mount Sinai | 2013-12-01 |
| Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience (NCT02485262) | Arrowhead Regional Medical Center | 2013-11-01 |
| Quantification of Side Effects During Hepatitis C Therapy (NCT02545400) | Medical University of Graz | 2013-11-01 |
| Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis (NCT02856243) | Assistance Publique - Hôpitaux de Paris | 2013-11-01 |
| Register of Telaprevir and Boceprevir in Routine Clinical Practice (NCT02004379) | Fundación Pública Andaluza Progreso y Salud | 2013-11-01 |
| Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003) (NCT01930058) | Merck Sharp & Dohme LLC | 2013-10-02 |
| Intensive Models of HCV Care for Injection Drug Users (NCT01857245) | Prisma Health-Upstate | 2013-10-01 |
| Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases (NCT01988753) | Baylor College of Medicine | 2013-10-01 |
| A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects (NCT02597790) | University of California, Los Angeles | 2013-10-01 |
| Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047) (NCT01932762) | Merck Sharp & Dohme LLC | 2013-10-01 |
| A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010) (NCT01537900) | Merck Sharp & Dohme LLC | 2013-10-01 |
| Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients (NCT01970904) | Debiopharm International SA | 2013-10-01 |
| SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection (NCT01962441) | Gilead Sciences | 2013-09-24 |
| Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1 (NCT01890772) | Timothy Morgan, MD | 2013-08-01 |
| Immune Response in Patients With Hepatitis B and C Infection (NCT02275221) | Mid and South Essex NHS Foundation Trust | 2013-08-01 |
| Dutch Acute HCV in HIV Study (DAHHS) (NCT01912495) | Erasmus Medical Center | 2013-08-01 |
| An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C (NCT01889433) | Biocad | 2013-07-10 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection (NCT01924949) | Gilead Sciences | 2013-07-01 |
| Blood Collection Biorepository for Liver Disease Research (NCT03025074) | State University of New York at Buffalo | 2013-07-01 |
| An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients (NCT02103439) | Biocad | 2013-06-06 |
| A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study (NCT01773070) | AbbVie (prior sponsor, Abbott) | 2013-06-01 |
| Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection (NCT01909804) | Gilead Sciences | 2013-06-01 |
| Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects (NCT01856426) | Enanta Pharmaceuticals, Inc | 2013-06-01 |
| Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) (NCT02768545) | Pontificia Universidad Catolica de Chile | 2013-06-01 |
| A Health Intervention to Prevent Depression Hepatitis C Patients (NCT01890083) | University of Texas Southwestern Medical Center | 2013-06-01 |
| A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C (NCT01842451) | Vertex Pharmaceuticals Incorporated | 2013-06-01 |
| Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV (NCT01878799) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-06-01 |
| Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (NCT01827657) | GlaxoSmithKline | 2013-05-28 |
| Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C) (NCT01846494) | Duke University | 2013-05-10 |
| New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C (NCT01888900) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2013-05-01 |
| Implementation of a Sexual Health Intervention for Young Men Who Have Sex With Men (MSM) in Two Vietnamese Cities (NCT02122094) | National Development and Research Institutes, Inc. | 2013-05-01 |
| Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C (NCT01833845) | BioLineRx, Ltd. | 2013-04-01 |
| THISTLE - The HIV-HCV Silibinin Trial (NCT01816490) | University of Zurich | 2013-04-01 |
| Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C (NCT01821625) | University of Texas Southwestern Medical Center | 2013-04-01 |
| Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection (NCT01858766) | Gilead Sciences | 2013-04-01 |
| HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin (NCT01718301) | Anna Cruceta | 2013-03-10 |
| Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (NCT01795911) | Bristol-Myers Squibb | 2013-03-01 |
| A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients (NCT01567540) | Institut National de la Santé Et de la Recherche Médicale, France | 2013-03-01 |
| A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035) (NCT01717326) | Merck Sharp & Dohme LLC | 2013-02-07 |
| A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105) (NCT01756079) | Merck Sharp & Dohme LLC | 2013-02-06 |
| Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3 (NCT01808248) | Gilead Sciences | 2013-02-01 |
| Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C (NCT02123212) | National Opinion Research Center | 2013-02-01 |
| Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests (NCT01790633) | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | 2013-02-01 |
| Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection (NCT01910636) | Gilead Sciences | 2013-02-01 |
| A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039) (NCT01716156) | Merck Sharp & Dohme LLC | 2013-01-18 |
| Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy (NCT01718158) | Bristol-Myers Squibb | 2013-01-01 |
| The Pathogenesis of Hepatitis C Virus Vertical Transmission (NCT01921400) | University of North Carolina, Chapel Hill | 2013-01-01 |
| An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus (NCT01701063) | Vertex Pharmaceuticals Incorporated | 2013-01-01 |
| European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol (NCT04677842) | PENTA Foundation | 2013-01-01 |
| Integrated Stepped Care for Unhealthy Alcohol Use in HIV (NCT01410123) | Yale University | 2013-01-01 |
| Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome (NCT02083367) | OSF Healthcare System | 2013-01-01 |
| Brief Intervention for Rural Women at High Risk for HIV/HCV (NCT01840722) | Michele Staton | 2012-12-01 |
| In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia (NCT01726400) | Fremantle Hospital and Health Service | 2012-12-01 |
| The Boceprevir and Sildenafil Pharmacokinetics Study (NCT01499498) | Imperial College London | 2012-12-01 |
| Integrating HIV and Hepatitis C Screening in an Urban Emergency Department (NCT03252483) | New York City Health and Hospitals Corporation | 2012-12-01 |
| Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C (NCT01727934) | Santaris Pharma A/S | 2012-11-01 |
| A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189) (NCT01732848) | Bristol-Myers Squibb | 2012-11-01 |
| Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) (NCT01667081) | Merck Sharp & Dohme LLC | 2012-10-17 |
| Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis (NCT01707472) | Gilead Sciences | 2012-10-04 |
| An Observational Study of Hepatitis C Virus in Pregnancy (NCT01959321) | The George Washington University Biostatistics Center | 2012-10-01 |
| Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease (NCT01654939) | Douglas T. Dieterich | 2012-10-01 |
| 3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals (NCT01721265) | Merck Sharp & Dohme LLC | 2012-10-01 |
| Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules (NCT01704846) | Boehringer Ingelheim | 2012-10-01 |
| Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients (NCT01433133) | Medgenics Medical Israel Ltd. | 2012-10-01 |
| Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment (NCT01830205) | Bristol-Myers Squibb | 2012-09-01 |
| Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (NCT01682720) | Gilead Sciences | 2012-09-01 |
| Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone (NCT01637922) | Boehringer Ingelheim | 2012-08-01 |
| Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies (NCT01715779) | Novartis | 2012-08-01 |
| Boceprevir and Ucalm (St John&Apos;s Wort) (NCT01663922) | St Stephens Aids Trust | 2012-08-01 |
| Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults (NCT01667731) | Gilead Sciences | 2012-07-01 |
| Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation (NCT01687257) | Gilead Sciences | 2012-07-01 |
| Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects (NCT01646489) | Santaris Pharma A/S | 2012-06-01 |
| Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes (NCT01625793) | University of Arizona | 2012-06-01 |
| Clinical Performance Evaluation of DxN HCV Assay (NCT03125408) | Beckman Coulter, Inc. | 2012-05-02 |
| Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India (NCT01772121) | Gilead Sciences | 2012-05-01 |
| A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1) (NCT01593735) | Merck Sharp & Dohme LLC | 2012-05-01 |
| A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers (NCT01549496) | Ottawa Hospital Research Institute | 2012-05-01 |
| Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin (NCT01425970) | Bristol-Myers Squibb | 2012-05-01 |
| Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment (NCT01585584) | University of Calgary | 2012-05-01 |
| Hepatitis C Rimantadine and Antiviral Combination Therapy (NCT01413490) | The Leeds Teaching Hospitals NHS Trust | 2012-05-01 |
| Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients (NCT01592006) | University of Chicago | 2012-04-01 |
| Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment (NCT01580306) | Boehringer Ingelheim | 2012-04-01 |
| Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir (NCT01582035) | Janssen R&D Ireland | 2012-04-01 |
| Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial (NCT01579474) | Boehringer Ingelheim | 2012-04-01 |
| Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection (NCT01482767) | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-04-01 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients (NCT01567735) | Janssen R&D Ireland | 2012-03-27 |
| Staged Phase I/II Hepatitis C Prophylactic Vaccine (NCT01436357) | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-03-06 |
| Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant (NCT01559844) | Gilead Sciences | 2012-03-01 |
| Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial (NCT01525810) | Bristol-Myers Squibb | 2012-03-01 |
| A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C (NCT01591668) | Gilead Sciences | 2012-03-01 |
| Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant (NCT01603108) | Columbia University | 2012-03-01 |
| Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients (NCT01701336) | ReiThera Srl | 2012-03-01 |